Search

Your search keyword '"Diquet B"' showing total 318 results
Start Over Author "Diquet B"
318 results on '"Diquet B"'

3. Impact of the first wave of the COVID-19 pandemic on French Health students

Author

Rolland, F., Frajerman, A., Falissard, B., Bertschy, G., Diquet, B., and Marra, D.

Abstract

In France, care workers and health students have been intensely mobilized during the first wave of the COVID-19 pandemic. But few studies have evaluated psychological distress on non-medical health students, in addition to the challenges posed by pedagogical continuity while universities are closed following health and safety regulations.

Published
2023
Full Text
View/download PDF

6. Patterns of quadruple therapy use including bismuth for Helicobacter pylori eradication: A cohort study in the French national claims database

Author

Blin, Patrick, Rouyer, Magali, Guiard, Estelle, Zerbib, F., DIQUET, B., MEGRAUD, F., Tison, F., Abouelfath, Abdelilah, Lassalle, R., DROZ-PERROTEAU, Cecile, Moore, Nicholas, Bordeaux population health (BPH), and Université de Bordeaux (UB)-Institut de Santé Publique, d'Épidémiologie et de Développement (ISPED)-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
surgical procedures, operative, [SDV.SPEE]Life Sciences [q-bio]/Santé publique et épidémiologie
Abstract

BACKGROUND: Quadruple therapy using a single capsule formulation of bismuth, metronidazole and tetracycline (BMT; Pylera®), associated with omeprazole for the eradication of Helicobacter pylori, represents the reintroduction of bismuth in France after 40 years. OBJECTIVE: To describe the real-life patterns of use of BMT following a request from the French health authorities. METHODS: Patients with a first BMT dispensing (index date, ID), with one year of data before and after ID, were identified in the French nationwide claims database 1/97 sample. Misuse of BMT was defined as dispensing>1 pack of BMT at ID or absence of a diagnostic test in the preceding year. RESULTS: In total, 540 patients were included. Prescribers were gastroenterologists (n=243; 45%) and general practitioners (n=160; 30%). A proton pump inhibitor was co-dispensed to 504 patients (96%). Ten patients (2%) had contraindications to BMT. Fifty-nine patients (11%) met the misuse criteria: ten (2%) were dispensed>1 pack of BMT and 49 (9%) had not had a diagnostic test for H. pylori in the previous year. During follow-up, 27 patients (5%) required retreatment (treatment failure). CONCLUSION: In this real-life study, most patients were dispensed only one pack of BMT, consistent with recommendations. Misuse related principally to the absence of prior diagnostic test for H. pylori.

Published
2020

7. Méthodologie d’évaluation et de mesure du progrès thérapeutique

Author

Alexandre, J.-M., Amede-Manesme, O., Bader, J.-P., Bouhassira, M., Calles, B., Castaigne, A., Chauvenet, M., Diquet, B., Giri, I., Ichou, F., Jolliet, P., Joubert, J.-M., Lehner, J.-P., Lièvre, M., Mathiex-Fortunet, H., Marty, M., Meyer, F., Micallef, J., Pigeon, M., Rouveix, B., Zannad, F., Guillemot, Didier, France, Georges, and Fender, Pierre

Published
2005
Full Text
View/download PDF

8. Methodology for the Evaluation and Measurement of Therapeutic Progress

Author

Alexandre, J.-M., Amede-Manesme, O., Bader, J.-P., Bouhassira, M., Calles, B., Castaigne, A., Chauvenet, M., Diquet, B., Giri, I., Ichou, F., Jolliet, P., Joubert, J.-M., Lehner, J.-P., Lièvre, M., Mathiex-Fortunet, H., Marty, M., Meyer, F., Micallef, J., Pigeon, M., Rouveix, B., Zannad, F., Guillemot, Didier, France, Georges, and Fender, Pierre

Published
2005
Full Text
View/download PDF

13. Adaptation of the Clinical Trials Directive

Author

Berger, F., Bertoye, P.-H., Brion, N., Buntix, A., Caplain, H., Caulin, C., Courcier-Duplantier, S., Daurat, V., Demarez, J.-P., Diquet, B., Echemann, M., Funck-Brentano, C., Lamarque, V., Laurent, S., Libersa, C., Marey, C., Moore, N., Patat, A., Pinquier, J.-L., Reynier, J.-C., Sawaya, A., Sibenaler, C., Simon, N., Tremblay, D., Vella, P., Warot, D., Bélorgey, Chantal, Plétan, Yannick, and Goehrs, Jean-Marie

Published
2004
Full Text
View/download PDF

14. Transposition de la Directive Essais Cliniques

Author

Berger, F., Bertoye, P.-H., Brion, N., Buntix, A., Caplain, H., Caulin, C., Courcier-Duplantier, S., Daurat, V., Demarez, J.-P., Diquet, B., Echemann, M., Funck-Brentano, C., Lamarque, V., Laurent, S., Libersa, C., Marey, C., Moore, N., Patat, A., Pinquier, J.-L., Reynier, J.-C., Sawaya, A., Sibenaler, C., Simon, N., Tremblay, D., Vella, P., Warot, D., Bélorgey, Chantal, Plétan, Yannick, and Goehrs, Jean-Marie

Published
2004
Full Text
View/download PDF

18. In-vitro tests on Philippine isolates of Plasmodium falciparum against four standard antimalarials and four qinghaosu derivatives

Author

Bustos, M.D.G., Gay, F., and Diquet, B.

Subjects
Plasmodium falciparum -- Drug therapy, Antimalarials -- Evaluation
Abstract

In-vitro drug sensitivity tests were performed on Philippine isolates of Plasmodium falciparum between 1991 and 1993, using the radioisotope microdilution method. The success of the tests varied significantly with the level of parasitaemia, the source of the strains, the period that elapsed before culturing, and the detectable concentrations of antimalarials in the blood. There was a significant positive correlation between the [IC.sub.50] values for chloroquine and artesunate and the level of chloroquine in the blood before testing. In the Philippines the sensitivity profiles of the standard antimalarials chloroquine, quinine, mefloquine, and halofantrine) were less severe than those in other south-east Asian countries. Fairly low [IC.sub.50] values were obtained for the qinghaosu derivatives artemisinin, artemether, arteether and artesunate. There was a positive correlation between quinine, mefloquine, hatofantrine and some of the qinghaosu derivatives, and between the qinghaosu compounds themselves, raising the possibility of either cross-resistance or possible drug associations., Introduction During the early 1960s the resurgence of malaria was accompanied by the worldwide spread of chloroquine resistance from one or two foci in south-east Asia and South America. Compounding [...]

Published
1994

22. Pharmacogenetic and Pharmacogenomic Studies

Author

Arnoux, P.Y., Baumelou, E., Beaune, P.H., Boissel, J.P., Cambien, F., Cano-Petit, M., Deleuze, J.F., Diquet, B., Elion, J., Fluckiger, L., Funck-Brentano, C., Job, J.M., Lechat, Ph., Mignot, L., Mouly, S., de Curzon, A. Parent, Alhenc-Gelas, François, Parmentier, Laurent, and Bisagni, Anne

Published
2003
Full Text
View/download PDF

35. Placebo y efecto placebo

Author

Bardot, V., primary, Petron-Bardou, C., additional, Airagnes, G., additional, Le Covec, G., additional, and Diquet, B., additional

Published
2014
Full Text
View/download PDF

42. Effect of itraconazole on the pharmacokinetics of prednisolone and methylprednisolone and cortisol secretion in healthy subjects

Author

Lebrun-Vignes, B, Archer, V Corbrion, Diquet, B, Levron, J C, Chosidow, O, Puech, A J, and Warot, D

Subjects
Adult, Male, Bodily Secretions, Antifungal Agents, Cross-Over Studies, Hydrocortisone, Prednisolone, Humans, Drug Interactions, Itraconazole, Glucocorticoids, Methylprednisolone
Abstract

Itraconazole is a potent inhibitor of CYP3A4 activity and is often used in combination with corticosteroids. Since the latter are partly metabolized by CYP3A4, we studied the interaction between itraconazole, prednisone and methylprednisolone in healthy male subjects.The effects of 4 days administration of oral itraconazole (400 mg on the first day then 200 mg day-1 for 3 days) on the pharmacokinetics of prednisolone after a single oral dose of prednisone (60 mg) and the pharmacokinetics of methylprednisolone after single oral dose of methylprednisolone (48 mg) were studied in 14 healthy male subjects in a two-period cross-over trial. Plasma cortisol concentrations were determined as a pharmacodynamic index.Itraconazole increased the mean area under the methylprednisolone concentration-time curve from 2773 ng ml-1 h to 7011 ng ml-1 h (P0.001) and the elimination half-life from 3.2 h to 5.5 h (P0.001). The pharmacokinetics of prednisolone were unchanged. Cortisol concentrations at 24 h were lower after administration of methylprednisolone with itraconazole than after methylprednisolone alone (24 ng ml-1 vs 109 ng ml-1, P0.001).Itraconazole increased methylprednisolone concentrations markedly with enhanced suppression of endogenous cortisol secretion, but had no effect on prednisolone pharmacokinetics. The pharmacokinetic interaction between methylprednisolone and itraconazole is probably related to inhibition of hepatic CYP3A4 activity by itraconazole.

Published
2001

50. Quinidine

Author

Delhotal, B., primary, Compagnon, P., additional, and Diquet, B., additional

Published
2006
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results